Forte Biosciences Inc (FBRX) Stock Price, Quote & News

Company Profile

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Industry: Biotechnology

Sector: Healthcare

Phone: 310 618 6994

Website: www.fortebiorx.com

Address:

3060 Pegasus Park Drive, Building 6, Dallas, United States

G_D_1 Nov. 26 at 3:44 PM

$FBRX $ 22

0 · Reply

Doozio Nov. 25 at 5:45 PM

$FBRX et about it ?

0 · Reply

JarvisFlow Nov. 25 at 12:57 PM

Evercore ISI Group has adjusted their stance on Forte Biosciences ( $FBRX ), setting the rating to Outperform with a target price of 65.

0 · Reply

G_D_1 Nov. 25 at 12:54 PM

$FBRX Evercore ISI initiated coverage on Forte Biosciences Inc. (NASDAQ:FBRX) with an Outperform rating and a $65.00 price target, representing potential upside of 250% from the current price of $19.06. The $339.87 million market cap biotech company has analyst targets ranging from $19 to $75, with a strong buy consensus.

0 · Reply

G_D_1 Nov. 20 at 4:14 PM

$FBRX $21

0 · Reply

StockScanners Nov. 20 at 2:49 AM

$FBRX reached 20

0 · Reply

G_D_1 Nov. 19 at 8:33 AM

$FBRX $18

0 · Reply

StockScanners Nov. 19 at 3:39 AM

$FBRX keep watch if this holds above 16.87

0 · Reply

1inTheStink Nov. 19 at 3:27 AM

$FBRX could be a real sleeper

0 · Reply

topstockalerts Nov. 18 at 10:07 PM

Top Gainers PT2 $ONDS $TIVC $BTQ $FBRX $CYPH

0 · Reply

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

Nov 14, 2025, 9:00 AM EST - 20 days ago

Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update

Nov 3, 2025, 4:01 PM EST - 4 weeks ago

Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences

Oct 3, 2025, 4:01 PM EDT - 2 months ago

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Sep 15, 2025, 9:00 AM EDT - 2 months ago

Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium

Aug 14, 2025, 4:01 PM EDT - 3 months ago

Forte Biosciences, Inc. Announces Results and Provides Update

Jun 25, 2025, 12:28 AM EDT - 5 months ago

Forte Biosciences Announces Pricing of $75 Million Public Offering

Jun 24, 2025, 4:01 PM EDT - 5 months ago

Forte Biosciences Announces Proposed Public Offering

Jun 23, 2025, 7:18 AM EDT - 5 months ago

Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

Mar 31, 2025, 9:00 AM EDT - 8 months ago

Forte Biosciences, Inc. Announces Results and Provides Clinical Update

Feb 3, 2025, 9:00 AM EST - 10 months ago

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

Nov 25, 2024, 9:00 AM EST - 1 year ago

Forte Biosciences to Host R&D Day December 3, 2024

Nov 20, 2024, 9:00 AM EST - 1 year ago

Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications

Nov 14, 2024, 4:01 PM EST - 1 year ago

Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update

May 13, 2024, 4:05 PM EDT - 1 year ago

Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update

Mar 18, 2024, 4:05 PM EDT - 1 year ago

Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update

Nov 13, 2023, 4:01 PM EST - 2 years ago

Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update

Sep 14, 2023, 10:50 AM EDT - 2 years ago

ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company's Upcoming Annual Meeting

Sep 6, 2023, 3:15 PM EDT - 2 years ago

Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company's Boardroom

Aug 25, 2023, 8:00 AM EDT - 2 years ago

Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to Stockholders

Aug 14, 2023, 4:01 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update

Aug 1, 2023, 4:01 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102

May 15, 2023, 4:01 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business Update

Mar 31, 2023, 4:05 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update

Jan 12, 2023, 4:05 PM EST - 3 years ago

Mr. David Gryska Appointed to Forte Biosciences Board of Directors

Nov 14, 2022, 4:01 PM EST - 3 years ago

Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors

Nov 14, 2022, 4:01 PM EST - 3 years ago

Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update

Aug 17, 2022, 8:00 AM EDT - 3 years ago

Camac Partners Condemns Forte Biosciences' Seemingly Defensive and Unjustifiable Capital Raise

Aug 15, 2022, 4:05 PM EDT - 3 years ago

Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update

Jun 7, 2022, 9:00 AM EDT - 3 years ago

Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President

May 16, 2022, 9:00 AM EDT - 3 years ago

Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update

Sep 6, 2021, 12:42 PM EDT - 4 years ago

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

Sep 3, 2021, 2:31 PM EDT - 4 years ago

Why Forte Biosciences Stock Is Down Over 80% Today

Sep 3, 2021, 12:19 PM EDT - 4 years ago

A small biotech firm just plummeted 82% after abandoning a drug candidate due to failed phase 2 trial

Sep 3, 2021, 11:21 AM EDT - 4 years ago

Why Forte Biosciences Stock Is Imploding Today

Sep 3, 2021, 7:21 AM EDT - 4 years ago

Forte Biosciences stock plunges more than 80% after 'disappointing' trial results of atopic dermatitis treatment

Sep 2, 2021, 5:47 PM EDT - 4 years ago

Forte Biosciences Just Plummeted 80%: Here's Why

Sep 2, 2021, 4:05 PM EDT - 4 years ago

Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance

Aug 16, 2021, 4:05 PM EDT - 4 years ago

Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7

May 11, 2021, 7:24 AM EDT - 4 years ago

Forte Biosciences, Inc. (FBRX) CEO Paul Wagner on Q1 2021 Results - Earnings Call Transcript

May 10, 2021, 4:05 PM EDT - 4 years ago

Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update

May 3, 2021, 4:30 PM EDT - 4 years ago

Forte Biosciences, Inc. to Announce First Quarter 2021 Results and Provide a General Business Update

Apr 9, 2021, 6:07 AM EDT - 5 years ago

Forte Biosciences: Microbiome Therapeutics For Skin Disease

Apr 8, 2021, 6:59 PM EDT - 5 years ago

Forte Biosciences: FB-401 Could Become The First Line Topical Therapy In Atopic Dermatitis Market

Mar 29, 2021, 12:10 PM EDT - 5 years ago

Week 13 MDA Breakout Stocks - April 2021: Short-Term Picks To Give You An Edge

AMGN AXP CAT IMOM JPM UNH VRA

Mar 24, 2021, 8:00 AM EDT - 5 years ago

Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update

Mar 17, 2021, 4:05 PM EDT - 5 years ago

Forte Biosciences, Inc. to Announce 4Q and Full Year 2020 Results and Provide a General Business Update

G_D_1 Nov. 26 at 3:44 PM

$FBRX $ 22

0 · Reply

Doozio Nov. 25 at 5:45 PM

$FBRX et about it ?

0 · Reply

JarvisFlow Nov. 25 at 12:57 PM

Evercore ISI Group has adjusted their stance on Forte Biosciences ( $FBRX ), setting the rating to Outperform with a target price of 65.

0 · Reply

G_D_1 Nov. 25 at 12:54 PM

0 · Reply

G_D_1 Nov. 20 at 4:14 PM

$FBRX $21

0 · Reply

StockScanners Nov. 20 at 2:49 AM

$FBRX reached 20

0 · Reply

G_D_1 Nov. 19 at 8:33 AM

$FBRX $18

0 · Reply

StockScanners Nov. 19 at 3:39 AM

$FBRX keep watch if this holds above 16.87

0 · Reply

1inTheStink Nov. 19 at 3:27 AM

$FBRX could be a real sleeper

0 · Reply

topstockalerts Nov. 18 at 10:07 PM

Top Gainers PT2 $ONDS $TIVC $BTQ $FBRX $CYPH

0 · Reply

JarvisFlow Nov. 17 at 12:50 PM

Chardan Capital updates rating for Forte Biosciences ( $FBRX ) to Buy, target set at 61.

0 · Reply

BEATOFtheMARKET Nov. 17 at 12:23 AM

$EXPE $F $FAF $FBRX $FCFS

0 · Reply

BillionerOfKing Nov. 14 at 3:50 PM

$FBRX Current Stock Price: $13.97 Contracts to trade: $10 FBRX Nov 21 2025 Call Entry: $1.50 Exit: $2.39 ROI: 59% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

d_risk Nov. 14 at 2:10 PM

$FBRX - Forte Biosciences, Inc. - 10Q - Updated Risk Factors Forte’s updated 10-Q risk factors highlight deeper clinical, regulatory, and market uncertainties—especially for FB102—plus new risks from U.S. tax law changes, international development, IP disputes, reliance on third parties, and public company compliance, all amplifying financial and operational volatility. #Biotechnology #FinancialVolatility #IntellectualProperty #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/FBRX/10-Q/2025-11-14

0 · Reply

deedeethegenius Nov. 13 at 6:33 PM

1. $KURA (Nov 30) - Best risk/reward for conservative biotech investors 2. $COGT (Dec) - Already validated with +135% move; multiple shots on goal 3. $FBRX (Q4) - Strongest unusual options signal (1,663% spike

1 · Reply

Investmann Oct. 14 at 7:34 PM

$FBRX country club is talking about

0 · Reply

porky1963 Oct. 11 at 8:00 PM

$FBRX well lets try and predict the next few weeks,will biotech come out on top.i think so.maybe a roller coaster for crypto.

0 · Reply

Doozio Oct. 11 at 6:26 PM

$XBI don’t $FOLD unless yo gotta $AXSM body! If so? $FBRX about it . 🐒🍌🧠⏰♾️

0 · Reply

Doozio Oct. 11 at 3:32 PM

Gotta be on $DRUG zzzzzz to still be bullish. As long as no faatch 💣 lands. $FBRX etaboutit. 🐒🍌🧠⏰♾️

0 · Reply

Doozio Oct. 11 at 12:13 AM

Chop chop huckleberries. $FBRX etaboutit! 🐒🍌🧠⏰♾️

0 · Reply

Investmann Oct. 3 at 8:08 PM

$FBRX next stop 20$

0 · Reply

Investmann Sep. 30 at 2:55 PM

$FBRX big whales in.

0 · Reply

Market Cap	239.14M
Revenue (ttm)	0.00
Net Income (ttm)	-35.48M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	18,684
Avg Vol	103,538
Day's Range	N/A - N/A
Shares Out	12.53M
Stochastic %K	19%
Beta	3.26
Analysts	Strong Sell
Price Target	$63.75